Current price is more than the intrinsic value
Stock has been generating better return on equity than bank FD
Stock doesn't offer attractive dividend returns
Good time to consider, as stock is not in overbought zone
Stock not in ASM/GSM lists, not a lot of promoter holding is pledged and default probability is low
Syngene International Limited is a contract research company. It is engaged in providing contract research and manufacturing services in early-stage drug discovery and development to pharmaceutical and biotechnology companies.
Customise key metrics, see detailed forecasts, download stock data and more
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
11 hours ago•Economic Times
12 hours ago•The Hindu Businessline
12 hours ago•The Hindu Businessline
Syngene International Limited has informed the Exchange regarding a press release dated January 20, 2021, titled "Third quarter revenue fromoperations up 13% to Rs. 585 Cr.PAT up 11% to Rs. 102 Cr.". | Download
Syngene International Limited has informed the Exchange regarding a press release dated January 20, 2021, titled "Third quarter revenue fromoperations up 13% to Rs. 585 Cr.PAT up 11% to Rs. 102 Cr.". | Download
Final • Div/Share: ₹ 0.5
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Current price is more than the intrinsic value